Two Ways of Managing Blood Pressure During Clot-Dissolving Treatment for Stroke
Compares two blood pressure approaches in adults receiving clot-dissolving treatment for ischemic stroke.
Plain-language title generated from the registry record
Registry title: Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a stroke caused by a blocked blood vessel, who are about to get a clot-dissolving drug through a vein and have high blood pressure. It compares two ways of managing blood pressure during that treatment.
- Age
- 18 to 80 years (inclusive)
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke, with clot-dissolving treatment planned within 4.5 hours of onset. Blood pressure before treatment: top number 180 mmHg or higher, or bottom number 100 mmHg or higher, on two measurements within 2 minutes.
- Earlier treatment
- No oral low-molecular-weight heparin in the last 24 hours. No new oral anticoagulant in the last 48 hours. Warfarin only if INR is 1.7 or lower and PT is 15 seconds or less.
- Biomarker or test result
- Blood sugar must be between 2.8 and 22.2 mmol/L (50–400 mg/dL). Platelet count must be at least 100×10^9/L.
Main reasons for not taking part
- Bleeding in the brain on CT or MRI, or a past brain bleed
- Severe head injury, stroke, or brain or spine surgery in the last 3 months
- Large area of brain damage on scan, or very severe stroke (NIHSS score above 25)
- Pregnant or breastfeeding women
- Taking part in another drug or device trial
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07279259, who can take part
Where in China
- Shanghai East HospitalShanghai, ChinaContact: Gang LiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai East Hospital
- Trial code
- NCT07279259
- Record updated
- 21 January 2026
- Original description
This study is a Phase II, exploratory, prospective, multicenter, open-label, randomized controlled clinical trial with blinded endpoint assessment setting on the safety of an adjusted versus a conventional blood pressure management strategy during intravenous thrombolysis in AIS patients, with a key focus on the incidence of symptomatic intracranial hemorrhage (sICH).Read full original descriptionShow less
Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management, EAST-BP
This study is a Phase II, exploratory, prospective, multicenter, open-label, randomized controlled clinical trial with blinded endpoint assessment setting on the safety of an adjusted versus a conventional blood pressure management strategy during intravenous thrombolysis in AIS patients, with a key focus on the incidence of symptomatic intracranial hemorrhage (sICH).
Inclusion: Age 18 to 80 years (inclusive); Patients with acute ischemic stroke; Planned to receive intravenous thrombolysis within 4.5 hours of onset; Elevated blood pressure: Before receiving intravenous thrombolysis treatment, blood pressure is elevated: systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 100 mmHg (defined as two consecutive measurements within 2 minutes); Informed consent signed (or signed by a proxy).
Exclusion: Intracranial or spinal surgery within the last 3 months; major surgery within the last 2 weeks; arterial puncture at a site not easily compressed for hemostasis within the last 7 days; Currently participating in other drug or device clinical trials; Intracranial hemorrhage is indicated on CT or MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural or epidural hematoma); History of intracranial hemorrhage; severe head trauma or stroke within the last 3 months; Gastrointestinal or urinary system bleeding within the last 3 weeks; Active visceral hemorrhage, known bleeding diathesis or significant bleeding disorders within the past 6 months; Severe ischemic stroke (NIHSS score > 25); Epileptic seizures at the time of stroke onset; Various terminal diseases with an expected survival of ≤ 3 months; Any other physical conditions where the doctor deems participation in this study may be detrimental to the patient; mRS score > 2 before onset of the disease; Acute bleeding tendency, including platelet count < 100×10\^9/L or other bleeding tendencies; Received low-molecular-weight heparin orally within 24 hours; taking warfarin with INR > 1.7 or PT > 15 seconds; used a new oral anticoagulant within 48 hours; Blood glucose < 2.8 mmol/L or > 22.2 mmol/L; Intracranial tumors, giant intracranial aneurysms; Aortic dissection; Large area cerebral infarction indicated on head CT or MRI (infarction area > 1/3 of the middle cerebral artery territory); Pregnant or lactating women.